These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9400598)

  • 41. Development and evaluation of an HIV-1 transfection-neutralization assay.
    Back NK; Smit L; Hogervorst E; van Wijk AC; Goudsmit J; Tersmette M
    J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):531-8. PubMed ID: 7513760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
    McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
    Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
    Wrin T; Loh TP; Vennari JC; Schuitemaker H; Nunberg JH
    J Virol; 1995 Jan; 69(1):39-48. PubMed ID: 7983734
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic appearance of antigenic epitopes effective for viral neutralization during membrane fusion initiated by interactions between HIV-1 envelope proteins and CD4/CXCR4.
    Toda T; Kuwahara K; Kondo N; Matsuda Z; Maeda Y; Maeda K; Sakaguchi N
    Immunobiology; 2012 Sep; 217(9):864-72. PubMed ID: 22226668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
    Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
    Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals.
    Ratto-Kim S; Sitz KV; Scherer AM; Kim JH; Anderson DW; Nau ME; Mann DL; Akolkar PN; Gulwani-Akolkar B; Silver J; Birx DL
    J Immunol; 1997 Nov; 159(10):5162-7. PubMed ID: 9366447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    Bou-Habib DC; Roderiquez G; Oravecz T; Berman PW; Lusso P; Norcross MA
    J Virol; 1994 Sep; 68(9):6006-13. PubMed ID: 8057475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resting cell neutralization assay for HIV-1 primary isolates.
    Hioe C; Burda S; Chigurupati P; Xu S; Zolla-Pazner S
    Methods; 1997 Aug; 12(4):300-5. PubMed ID: 9245610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV sensitivity to neutralization is determined by target and virus producer cell properties.
    Mann AM; Rusert P; Berlinger L; Kuster H; Günthard HF; Trkola A
    AIDS; 2009 Aug; 23(13):1659-67. PubMed ID: 19581791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles.
    Valenzuela A; Blanco J; Callebaut C; Jacotot E; Lluis C; Hovanessian AG; Franco R
    J Immunol; 1997 Apr; 158(8):3721-9. PubMed ID: 9103436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.
    Moog C; Spenlehauer C; Fleury H; Heshmati F; Saragosti S; Letourneur F; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):19-27. PubMed ID: 8989423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
    J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops.
    Signoret N; de Jong J; Goudsmit J; Sattentau QJ
    AIDS Res Hum Retroviruses; 1997 Jan; 13(2):121-3. PubMed ID: 9007197
    [No Abstract]   [Full Text] [Related]  

  • 55. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target.
    Armstrong SJ; Dimmock NJ
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1397-402. PubMed ID: 8757979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
    Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
    J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.
    Hou W; Fang C; Liu J; Yu H; Qi J; Zhang Z; Yuan R; Xiong D; Gao S; Adam Yuan Y; Li S; Gu Y; Xia N
    Antiviral Res; 2015 Oct; 122():101-11. PubMed ID: 26259811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
    Fouts TR; Binley JM; Trkola A; Robinson JE; Moore JP
    J Virol; 1997 Apr; 71(4):2779-85. PubMed ID: 9060632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
    Painter SL; Biek R; Holley DC; Poss M
    J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
    Moore JP; Sattentau QJ; Clapham PR
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.